FHTX - CIK 0001822462
Foghorn Therapeutics Inc. trades as FHTX. In its fiscal 2025 annual report the company posted revenue of $30.91M, up 36.8% from the prior year and net income of -$74.28M. This page tracks Foghorn Therapeutics Inc. through 339 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Foghorn Therapeutics Inc.'s revenue grew from $430.00K to $30.91M, a compound annual growth rate of 135.1%. Net profit margin expanded from -16000.0% to -240.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
The largest companies sharing Foghorn Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Foghorn Therapeutics Inc. reported revenue of $30.91M for fiscal year 2025, an increase of 36.8% year over year.
In its latest fiscal year Foghorn Therapeutics Inc. reported a net loss of $74.28M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.